OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer ...

The ongoing EPIC clinical trial is the first randomized head-to-head comparison of two neonatal Fc receptor (FcRn)-targeting ...

“This is exciting because we have evidence to say that consuming about a cup of coffee a day is safe and potentially ...

Millions of people worldwide continue to experience lingering symptoms after COVID-19, a condition known as long COVID. These ...

Researchers led by St Michael's Hospital in Toronto report that ketogenic diets are associated with modest reductions in ...

Clinical trials are more connected and more closely examined than ever. Inspection readiness isn’t a last-minute document ...

Chemoradiotherapy (CRT) was preferred to radiotherapy alone in patients older than 65 years who had stage II nonsurgical non–small cell lung cancer (NSCLC), as overall survival (OS) and ...

Late-breaking results from clinical trials, debates about lifestyle choices and cardiovascular risk, and improving clinical care with generative AI are among the topics being presented by UC San ...

Maintaining a healthy blood sugar level can reduce your disease risk and give you more energy. These 15 habits help keep ...

There was an increase in the hepatic fat fraction, the long-term consequences of which are unknown, says Robert Rosenson.

What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger ...

Upending previous research, study finds no evidence of status-quo bias favoring standard care when two or more appropriate alternatives are presented.